GLP1R and type 2 diabetes mellitus: GLP-1R agonists (also known as GLP-1 analogues or incretin mimetics) have been approved by the US Food and Drug Administration for the treatment of T2D not only for their effect on glucose regulation but also for their beneficial effect on beta cell function [85] (Table 2 and Figure 2).